Allergan will acquire Vitae pharmaceuticals for $639 million.
Allergan announced on Sept. 14, 2016 the acquisition of Vitae Pharmaceuticals, a clinical-stage biotechnology company. Allergan will acquire the company for $21.00 per share, in cash, for a total of $639 million. Allergan said in a press announcement they anticipate the transaction closing by the end of 2016.
Vitae Pharmaceuticals has several dermatological products in its pipeline including VTP-43742, a Phase II, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. Vitae also has VTP-38543, a topical LXRβ (Liver X Receptor beta) selective agonist for the potential treatment of atopic dermatitis. Vitae uses its Contour structure-based drug design platform to discover product candidates for validated therapeutic targets. In a note to investors, Umer Raffat of Evercore ISI notes Vitae also has a Phase I-ready BACE inhibitor for Alzheimer’s disease in its pipeline.
On Sept. 6, 2016, Allergan also announced the acquisition of RetroSense Therapeutics, a private, clinical-stage biotechnology company focused on using gene-therapy to restore vision in blind patients. Allergan paid $60 million upfront for the biotechnology company, with the potential for milestone payments.
Source: Allergan
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.